Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Inmune Bio Inc (NQ: INMB ) 6.000 -0.220 (-3.54%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Inmune Bio Inc < Previous 1 2 3 4 5 Next > INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA December 18, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium November 29, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease November 27, 2023 From INmune Bio, Inc. Via GlobeNewswire Earnings Outlook For INmune Bio August 04, 2023 Via Benzinga INmune Bio's Earnings Outlook May 02, 2023 Via Benzinga INmune Bio Earnings Perspective: Return On Capital Employed March 08, 2023 Via Benzinga Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning November 17, 2023 Biotech companies are edging closer to finding the answers behind Alzheimer's disease. Via Investor's Business Daily INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe November 15, 2023 The Company received regulatory approval to extend its Phase II trial of XPro™ in individuals with early Alzheimer’s disease in Poland, with additional European Union (EU) countries expected to open... From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority October 31, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα October 30, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference October 17, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1 October 16, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference September 07, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease September 05, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference August 01, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7 July 31, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference. July 12, 2023 From INmune Bio, Inc. Via GlobeNewswire BioMedNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Announces New Findings to Be Presented at Annual AAIC July 11, 2023 Via Investor Brand Network INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease July 11, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology July 10, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer's Disease June 13, 2023 David Moss, CEO of INmune Bio (NASDAQ: INMB) was recently a guest on Benzinga’s All-Access. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023 June 01, 2023 Via Benzinga INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy May 24, 2023 From INmune Bio, Inc. Via GlobeNewswire BioMedNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives IND Clearance from FDA, Represents First Ever Natural Killer Immunotherapy Trial for a Particular Cancer May 08, 2023 Via Investor Brand Network Exposures Product Safety INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer May 08, 2023 From INmune Bio, Inc. Via GlobeNewswire The 7 Best Biotech Stocks for Personalized Medicine Investors April 25, 2023 Personalized Medicine Stocks Promise to Make Healthcare More Individualized with therapeutics based on individual genetics. Via InvestorPlace INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3 April 24, 2023 From INmune Bio, Inc. Via GlobeNewswire XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease April 19, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03 April 11, 2023 From INmune Bio, Inc. Via GlobeNewswire INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer April 03, 2023 From INmune Bio, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.